Nucs AI

Deep learning on imaging is the entire product. All three tools do inference on PSMA PET/CT: automated lesion detection and whole body tumor burden quantification, response prediction to PSMA targeted radioligand therapy, and automated longitudinal response evaluation with lesion by lesion tracking. The company reports reducing manual analysis from roughly 30 minutes to about 1 minute, which is the kind of task no rules based software performs.

Positioned as decision support with the physician retaining the decision, and the products output quantified assessments and predictions rather than directives. The company formed a Medical Advisory Board spanning radiology, nuclear medicine, oncology, and clinical research, stating explicitly that the use of AI in clinical decision making places a higher premium on clinical oversight and evidence generation. Establishing that structure before broad commercialization is the right sequence, and the investigational labeling on the prediction product reinforces that a clinician is meant to be in the loop.

Products are described functionally and the imaging modality and clinical context are specific, but no model architecture, training data provenance, or performance figures are published on the company's own materials beyond references to preliminary multicenter results. The published scientific citations relate to the underlying clinical problem rather than to the models themselves.

Evidence is early and honestly labeled as such. The company states preliminary multicenter results show its prediction model identifies which metastatic castration resistant prostate cancer patients will respond to Lutetium PSMA therapy, and cites collaborations with Johns Hopkins and other research institutions. The strongest external validation is commercial rather than clinical: a pharmaceutical collaboration to develop response prediction models for a PSMA targeted radioconjugate, which is a substantial third party bet on the platform. What does not yet exist publicly is a peer reviewed prospective validation of the products as deployed.

No published PHI handling, encryption, or data governance disclosure was located. The platform processes whole body PET/CT imaging, which is identifiable patient data, and the company also states it combines proprietary datasets with its models, so provenance and consent for training data are questions a buyer should raise directly.

No HIPAA or BAA commitment located in public materials. The company is early stage, founded 2024, and serving research and pharmaceutical partners alongside clinical sites, so a buyer should establish this rather than assume it.

No SOC 2, ISO 27001, or equivalent attestation was located. Consistent with company stage rather than an unusual gap, but it is a real one for any health system considering deployment.

The company deserves credit for stating this plainly where many would obscure it. Its own product page carries the disclaimer that SelectPSMA is an investigational tool, has not been cleared or approved by the FDA or any other regulatory body, and is not intended for clinical diagnostic use. Separately, the company has publicly named achieving FDA clearance for its detection and selection products as a forward looking objective rather than an accomplished fact. A buyer should read the entire suite as pre clearance and confine use to research and investigational contexts until that changes. The grade reflects candid disclosure of an unfavorable status, not regulatory achievement.

No governance framework or bias evaluation was located. The Medical Advisory Board is a clinical oversight structure rather than an AI governance program, and no disclosure addresses performance variation across scanner types, imaging protocols, or patient populations, all of which are known sources of drift in imaging AI.

No EHR integration is evidenced. The company describes clinical grade infrastructure supporting clinicians, researchers, OEMs, and pharmaceutical partners, and offers structured CSV export for biomarker and radiomics work, which suggests the practical integration surface today is PACS and research pipelines rather than the chart.

No hosting, tenancy, or residency disclosure was located.

No published pricing and no described commercial model. The buyer set spans hospitals, research institutions, imaging OEMs, and pharmaceutical partners, and each of those would carry different commercial structures, none of which are public.

Deliberately narrow and explicit about it: prostate cancer via PSMA PET/CT, with the products spanning detection, patient selection for radioligand therapy, and response monitoring across that single pathway. The company states an intent to expand beyond prostate cancer into broader oncology and advanced imaging, which should be treated as roadmap rather than current capability.